Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
Liver International 40:2860-2876, 2020
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Nature Metabolism 2(5):413–431, 2020
Activation of adenosine monophosphate-activated protein kinase reduces the onset of diet-induced hepatocellular carcinoma in mice
Hepatology Communications 4(7):1056-1072, 2020
Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
BMC Gastroenterology 19(1):228, 2019
Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
In: Krentz A., Weyer C., Hompesch M. (eds) Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. Springer, Cham. pp 369-403, 2019
INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
World Journal of Gastroenterology 24(2):195–210, 2018